Presidential Cancer Panel's Drug Value, Affordability Recommendations Align With Industry Views

Panel recommends National Academies of Sciences evaluate value frameworks like ICER, identify limitations and strengths and, if necessary, develop a new approach.

US-Money-and-Pills_V2_1200x675

The President's Cancer Panel urges improvements in value frameworks and expanded insurance coverage as ways to better align prices with value and enhance the affordability of cancer drugs in a report released March 13.

Entitled "Promoting Value, Affordability and Innovation in Cancer Drug Treatment," the report offers six recommendations that align with biopharma industry priorities (see box). It does not advise government price controls....

Members of the three-person panel include Barbara Rimer, dean of the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill, actor and philanthropist Hill...

More from Pricing Debate

More from Market Access